Company NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-03 pm EST			5-day change	1st Jan Change
30.51 ^USD	+2.21%		+70.64%	+104.35%

Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
Dec. 02	NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	MT

Business description: NovoCure Limited

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Number of employees: 1,453

Sales by Activity: NovoCure Limited

Fiscal Period: December	2019	2020	2021	2022	2023
Surgical & Medical Equipment	351M	494M	535M	538M	509M

See all business segments

Geographical breakdown of sales: NovoCure Limited

Fiscal Period: December	2019	2020	2021	2022	2023
United States	233M	341M	353M	407M	350M
Germany	86.56M	93.26M	93.94M	46.12M	60.21M
Other International Markets	-	-	-	-	44.49M
Japan	17.91M	29.08M	34.64M	32.78M	31.67M
Greater China	5.26M	12.59M	22.76M	21.33M	23.22M
Europe, Middle East and Africa (EMEA) (Excluding Germany)	8.78M	18.65M	30.58M	30.71M	-

See all geographic segments

Managers: NovoCure Limited

Director	Title	Age	Since
Asaf Danziger CEO	Chief Executive Officer	57	2001-12-31
Ashley Cordova DFI	Director of Finance/CFO	45	2020-08-31
Nicolas Leupin CTO	Chief Tech/Sci/R&D Officer	50	2024-01-03
Moshe Giladi CTO	Chief Tech/Sci/R&D Officer	-	2023-01-16
Ingrid Goldberg IRC	Investor Relations Contact	-	2021-06-30

See NOVOCURE LIMITED governance

Members of the board: NovoCure Limited

Manager	Title	Age	Since
Asaf Danziger BRD	Director/Board Member	57	2011-12-31
Bill Doyle CHM	Chairman	61	2008-12-31
Kin Yip Leung BRD	Director/Board Member	63	2011-08-04
Tony Vernon BRD	Director/Board Member	69	2005-12-31
Martin Madden BRD	Director/Board Member	64	2017-05-09
David Hung BRD	Director/Board Member	67	2018-05-30
Jeryl Hilleman BRD	Director/Board Member	67	2018-07-24
Timothy Scannell BRD	Director/Board Member	60	2021-02-04
Allyson Ocean BRD	Director/Board Member	53	2023-02-22
Kristin Stafford BRD	Director/Board Member	43	2023-03-27

Composition of the Board of Directors

Shareholders: NovoCure Limited

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 15.00 %	16,232,008	15.00 %	246 M $
Vanguard Fiduciary Trust Co. 10.95 %	11,844,608	10.95 %	180 M $
BlackRock Advisors LLC 10.35 %	11,200,866	10.35 %	170 M $
Hansjörg Wyss 7.523 %	8,141,397	7.523 %	124 M $
Capital Research & Management Co. (International Investors) 7.321 %	7,922,761	7.321 %	120 M $

Name	Equities	%	Valuation
BRAM - Bradesco Asset Management SA DTVM 0.000064 %	692	0.000064 %	1 121 $

List of NOVOCURE LIMITED shareholders

Company details: NovoCure Limited

NovoCure Ltd.

No. 4 The Forum Grenville Street

JE2 4UF, St. Helier

+44 15 3475 6700

http://www.novocure.com

Medical Equipment

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
NOVOCURE LIMITED	+2.21%	+70.64%	+144.08%	-62.82%	3.3B
SHOCKWAVE MEDICAL	-0.01%	+0.01%	+83.75%	+102.74%	12.57B
PENUMBRA, INC.	+0.16%	-1.49%	+7.68%	+3.01%	9.41B
MASIMO CORPORATION	+1.46%	+1.12%	+80.12%	-37.11%	9.33B
APT MEDICAL INC.	+2.89%	+4.05%	+43.38%	+77.57%	4.97B
ASAHI INTECC CO., LTD.	+0.99%	-0.85%	-3.46%	+13.20%	4.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	-0.58%	-2.10%	+0.92%	-1.42%	4.69B
GETINGE AB	+1.19%	+1.67%	-24.75%	-54.99%	4.16B
INARI MEDICAL, INC.	-1.09%	+1.42%	-15.77%	-33.64%	3.02B
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD	-0.56%	+2.77%	-31.77%	-56.37%	1.56B
Average	+0.67%	+7.46%	+28.42%	-4.98%	5.78B
Weighted average by Cap.	+0.68%	+4.27%	+40.64%	+13.67%